
Cancer biomarkers
Biomarkers by Therapy Indication
- Autoimmune Disease and Arthritis Biomarkers
- Bone Disease Biomarkers
- Cancer Biomarkers
- Cardiovascular Biomarkers
- Cytokine and Chemokine Biomarkers
- Diabetes and Metabolic Biomarkers
- Endocrine Biomarkers
- Gastrointestinal Biomarkers
- Neuroscience Biomarkers
- Inflammation and Immune Response Biomarkers
- Kidney Function and Toxicity Biomarkers
RBM offers numerous biomarkers associated with oncogenesis, the processes that cause normal cells to become cancerous. Our markers are useful in evaluating new therapeutics for solid tumors and blood cancers.
Carcinoembryonic Antigen (CEA) and Alpha-Fetoprotein (AFP) are used as tumor markers for colorectal and liver cancers, respectively. CA-125 is a marker for ovarian cancer, while PSA is used for prostate cancer. HER2/neu is important for breast cancer prognosis and treatment decisions. BRCA1/BRCA2 mutations are associated with increased risk of breast and ovarian cancers. KRAS and EGFR mutations are relevant in colorectal and non-small cell lung cancers, guiding targeted therapies. BRAF mutations are significant in melanoma, and PD-L1 expression is a key biomarker for immunotherapy response. Ki-67 is a proliferation marker indicating tumor growth rate.
Multiplexes with cancer biomarkers
The biomarkers below have demonstrated links to solid tumors and blood cancers in the scientific literature.